John Costello, DO
Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1699037291
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (38.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 39.4% of the total. Reporting peaked in 2019 at $15,413 and has fallen 56.9% since, to $6,639 in 2025.
Across 404 payments — averaging $80.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Boston Scientific$8K
- Abbott$4K
- Biosense Webster, Inc.$2K
- Impulse Dynamics (USA) Inc.$1K
- Biotronik Inc.$1K
- plus $4K from 28 others
Across 13 payments — averaging $5327.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biosense Webster, Inc.$57K
- ZOLL Respicardia, Inc.$9K
- Impulse Dynamics (USA) Inc.$4K
What the payments were for
- Consulting fees$9213%
- Speaking & faculty fees$5,05015%
- Grants$12,50038%
- Travel & lodging$1,9276%
- Food & beverage$11,77536%
- Education$4141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 7 | $12,843 |
| Boston Scientific | 75 | $7,552 |
| Abbott | 72 | $3,676 |
| Biosense Webster, Inc. | 36 | $1,631 |
| Impulse Dynamics (USA) Inc. | 47 | $1,411 |
| Biotronik Inc. | 25 | $1,183 |
| Philips North America LLC | 9 | $869 |
| Atricure, Inc. | 24 | $859 |
| ZOLL Respicardia, Inc. | 1 | $352 |
| Elutia, Inc. | 6 | $345 |
| Cvrx, Inc. | 6 | $341 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $261 |
| Pfizer | 13 | $202 |
| Johnson & Johnson | 12 | $171 |
| Merck | 8 | $116 |
| Novartis | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 7 | $92 |
| Bayer | 4 | $84 |
| W. L. Gore & Associates, Inc. | 4 | $65 |
| Boehringer Ingelheim | 4 | $63 |
| Cardiva Medical, Inc. | 2 | $47 |
| Amarin Pharma, Inc. | 3 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Amgen | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Kestra Medical Technology Services, Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Stryker | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Inari Medical, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Farapulse$5,272
- Ensite Cardiac Mapping System$1,171
- GENERAL - THERAPIES$700
- (9124) LM Undivided$669
- WATCHMAN Access System$410
- AMPLATZER$398
- remede System$352
- ECM Patch,Pouch$271
- Carto 3 System$234
- Carto 3$221
- OPTIMIZER SMART SYSTEM$209
- Barostim Neo System$186
- EP-WorkMate Claris System$139
- Edora$137
- BioMonitor$137
- Acticor$137
- Rivacor$137
- Solia$137
- Acticor 7 VR-T DX$132
- Edora 8 DR-T$132
How this compares
$32,587 in reported general payments places this provider in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $201,842 |
| XareltoRivaroxaban | 40 | $55,274 |
| EntrestoSacubitril/Valsartan | 24 | $26,025 |
| FarxigaDapagliflozin Propanediol | 16 | $9,430 |
| Metoprolol Succinate | 88 | $1,671 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $668 |
| Atorvastatin Calcium | 35 | $632 |
| Metoprolol Tartrate | 79 | $575 |
| Rosuvastatin Calcium | 28 | $536 |
| Digoxin | 22 | $489 |
| Carvedilol | 36 | $333 |
| Amiodarone Hcl | 15 | $206 |
| Amlodipine Besylate | 25 | $205 |
| ClopidogrelClopidogrel Bisulfate | 14 | $203 |
| Furosemide | 29 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $201,842158 claims |
| Johnson & JohnsonXarelto | $171 | $55,27440 claims |
| NovartisEntresto | $100 | $26,02524 claims |
| AstraZenecaFarxiga | $15 | $9,43016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Philadelphia
- Fermin GarciaPhiladelphia$684K
- Ralph VerdinoPhiladelphia$682K
- Pasquale SantangeliPhiladelphia$581K
- Francis MarchlinskiPhiladelphia$469K
- Joshua CooperPhiladelphia$405K
- Timothy MarkmanPhiladelphia$402K
- David CallansPhiladelphia$350K
- Robert SchallerPhiladelphia$333K
- Matthew HymanPhiladelphia$294K
- David FrankelPhiladelphia$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.